Amylyx Pharmaceuticals, Inc. (AMLX)

Amylyx Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-301.74	-144.74	49.27	-198.38	-87.93
Depreciation & Amortization	0.53	0.9	1.09	0.49	0.05
Stock-Based Compensation	27.65	33.04	37.16	21.71	3.14
Other Adjustments	-5.7	145.99	-9.94	-2.06	5.35
Change in Receivables	0.36	39.6	-74.74	-15.31	-
Changes in Inventories	5.96	-9.25	-73.13	-9.77	-
Changes in Accounts Payable	0.58	-19.1	15.88	1.85	0.67
Changes in Accrued Expenses	-6.6	-59.81	21.6	26.05	8.43
Changes in Other Operating Activities	0.91	2.17	-5.27	-4.47	-4.51
Operating Cash Flow	-123.34	-167.65	11.92	-179.87	-74.8
Capital Expenditures	-0.14	-0.16	-1.24	-2.53	-0.35
Purchases of Intangible Assets	-	-36.2	-	-	-
Purchases of Investments	-231.82	-231.99	-300.83	-415.87	-49.05
Proceeds from Sale of Investments	246	344	394.12	179.41	3
Investing Cash Flow	14.04	75.65	92.05	-238.99	-46.41
Long-Term Debt Issued	-	-	-	-	26.16
Net Long-Term Debt Issued (Repaid)	-	-	-	-	26.16
Issuance of Common Stock	4.08	2.13	6.99	434.64	0.34
Net Common Stock Issued (Repurchased)	4.08	2.13	6.99	434.64	0.34
Issuance of Preferred Stock	-	-	-	-	135
Net Preferred Stock Issued (Repurchased)	-	-	-	-	135
Other Financing Activities	252.95	-1.78	-3.45	-2.85	-3
Financing Cash Flow	257.03	0.35	3.54	431.79	158.51
Effect of Exchange Rate Changes on Cash and Cash Equivalents	1.07	-0.44	0.16	-0.07	0.01
Net Cash Flow	148.8	-92.08	107.68	12.87	37.31
Free Cash Flow	-123.48	-167.8	10.68	-182.4	-75.15
FCF Margin	-	-192.06%	2.80%	-820.50%	-26369.12%
Free Cash Flow Per Share	-1.31	-2.46	0.15	-3.12	-11.41
Levered Free Cash Flow	-143.5	-386.99	8.2	-186.75	-57.48
Unlevered Free Cash Flow	-152.11	-399.57	-5.86	-190.5	-78.39

Updated Mar 3, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q